Search results (537)
« Back to PublicationsCorrection: Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.
Journal article
Buckell J. et al, (2026), Br J Cancer, 134, 175 - 176
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.
Journal article
Sato T. et al, (2025), Clin Cancer Res, 31, 5027 - 5036
Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2025)
Figure 6 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2025)
Figure 1 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2025)
Figure 4 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2025)
Figure 2 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2025)
Figure 3 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2025)
Figure 5 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2025)
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
Journal article
Wong MK. et al, (2025), J Clin Oncol, 43, 3589 - 3599
Patient characteristics, serious disease diagnoses, and incidental findings in individuals with non-specific symptoms referred to the Suspected CANcer (SCAN) Pathway: a prospective cohort study in England
Journal article
Friedemann Smith C. et al, (2025), The Lancet Primary Care, 1, 100019 - 100019
Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.
Journal article
Buckell J. et al, (2025), Br J Cancer, 133, 394 - 403
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
Journal article
Milotay G. et al, (2025), Nat Med, 31, 2350 - 2364
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.
Journal article
Dummer R. et al, (2025), Clin Cancer Res, 31, 2097 - 2107
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.
Journal article
Weber JS. et al, (2025), J Clin Oncol, 43, 929 - 937